<DOC>
	<DOCNO>NCT01638715</DOCNO>
	<brief_summary>The purpose study find biological response pattern patient rheumatoid arthritis drug different biologic mode action . This study help predict therapeutic response find right therapy right patient .</brief_summary>
	<brief_title>A Randomized , Multi-Center Biomarker Trial Predict Therapeutic Responses Patients With Rheumatoid Arthritis Specific Biologic Mode Action</brief_title>
	<detailed_description>The investigator propose randomise , multi-centre strategic biomarker trial rheumatoid arthritis ( RA ) patient failure methotrexate leflunomide one four current biological mode action : targeting TNF ( infliximab ) ; co-stimulation ( abatacept ) ; IL-6R ( tocilizumab ) ; B cell ( rituximab ) ; agent license RA evidence efficacy indication . Predictors response therapy 24 week analyse , include baseline follow assessment clinical , functional , structural , laboratory test ( routine , autoantibody , cytokine , gene expression , susceptibility gene ) . In second phase , patient achieve LDA/REM randomise one remain MoA . Two hundred patient , start new biological therapy enrol estimated period 5 year ; 50 patient per group include , study period 12 month .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>1 . Men woman , ≥18 ≤75 year age , capable understand signing informed consent . 2 . Classifiable RA accord 2010 ACR/EULAR criterion ( American College Rheumatology/European League Against Rheumatism classification criterion ) 1987 ARA criterion ( Criteria American Rheumatology Association ) ( present past ) ( 2 ; 3 ) 3 . Duration RA ≤3 year 4 . Ongoing conventional DMARD therapy ( Disease Modifying Antirheumatic Drugs ) methotrexate ( least 20mg/week , low tolerate high dos ) leflunomide ( ≥100mg/week ) , ≥6 month ≥3 month document worsen disease activity . 5 . Clinical Disease Activity Index ( CDAI ) ≥15 correspond moderate severe disease activity . 1 . Be incapacitate , largely wholly bedridden , confined wheelchair , little ability self care . 2 . Weigh 100 kg 3 . Use glucocorticoid &gt; 10 mg/day prednisone equivalent 4 . Have previously receive treatment rheumatic disease : 1. intramuscular intraarticular injection steroid previous month . 2. monoclonal antibody antibody fragment , licence investigational 3. investigational drug within 3 month prior screen within 5 halflives investigational agent , whichever longer . 4 . Azathioprine cytostatic drug . 5 . Have history receive human/murine recombinant product know allergy murine product . 6 . Have documentation seropositivity human immunodeficiency virus ( HIV ) , positive test hepatitis B surface antigen hepatitis C ¬antibodies . 7 . Have hypergammaglobulinemia 8 . Have history alcohol substance abuse within precede 6 month . 9 . Have know history 1. serious infection ( , limit hepatitis , pneumonia , pyelonephritis ) previous 3 month . 2. opportunistic infection ( eg , herpes zoster , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 12 month prior screen . 3. chronic recurrent infectious disease ( eg , chronic renal infection , chronic chest infection , COPD , sinusitis , recurrent urinary tract infection , open , drain infected skin wound ulcer etc. ) . 10 . Have undergone joint replacement surgery . 11 . Be men woman childbearing potential without use adequate birth control measure ( e.g. , abstinence , oral contraceptive , intrauterine device , barrier method spermicide , implantable injectable contraceptive surgical sterilization ) , willingness continue precaution duration study 6 month receive last medication . 12 . Be consider ineligible accord tuberculosis ( TB ) eligibility assessment screening , show positive test latent Tbc use Quantiferon assay , unless treatment INH instal least 2 week prior start trial drug . 13 . Show evidence malignancy , lymphoproliferative disease , history malignancy within previous 5 year , exception basal cell squamous cell carcinoma skin fully excise evidence recurrence . 14 . Have current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral disease . 15 . Be unable unwilling undergo multiple venipuncture poor tolerability lack easy access . 16 . Have presence transplant solid organ ( exception corneal transplant &gt; 3 month prior screen ) . 17 . Have concomitant diagnosis history congestive heart failure ( New York Heart Association NYHA class III IV ) diverticulitis . 18 . Have know history demyelinate disease , multiple sclerosis . 19 . Be woman pregnant , nursing , plan pregnancy within 6 month last infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Biologic therapy</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Mode Action</keyword>
</DOC>